Abstract
The early risk assessment of preeclampsia (PE) remains challenging in current clinical practice. We hypothesized that impending PE events can be predicted, when asymptomatic early in gestation, through the determination of the serum levels of leptin (Lep), a placental functions regulatory cytokine, and ceramide (Cer), a sphingolipid with anti-angiogenic and pro-apoptotic roles. Sera from two independent cohorts of PE and control women were assembled (Testing Cohort: 7 non-PE and 8 PE women sampled at confirmatory diagnoses; Validation Cohort: 20 non-PE and 20 PE women sampled longitudinally through gestation). Our multi-omics approach, integrating global genomic and lipidomic discoveries, revealed a marked elevation of the Lep/Cer (d18:1/25:0) ratio in PE women. Longitudinal analyses of Lep/Cer ratio can predict a median of 23 weeks before PE confirmative diagnosis. Sensitivity, positive predictive value, and AUC of the Lep/Cer (d18:1/25:0) ratio were 85%, 89%, and 0.92. Therefore, serum elevations of Lep/Cer (d18:1/25:0) ratio can be used to assess risk for impending PE during early asymptomatic pregnancies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study approval was obtained from ProMedDX Inc. and the Institutional Review Board at Stanford University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analyzed in this study are available upon request to the corresponding author.
List of Abbreviation
- ACC
- Acetyl-CoA carboxylase
- AUC
- Area Under the Curve
- AMPKK/AMPK
- AMP-activated protein kinase
- BMI
- Body Mass Index
- CPT1
- Carnitine Palmitoyltransferase 1
- Cer
- Ceramide
- CI
- Confidence Interval
- DHCer
- Dihydroceramide
- ELISA
- Enzyme-Linked Immunosorbent Assay
- FAO
- Fatty Acid Oxidation
- GEO
- Gene Expression Omnibus
- Lep
- Leptin
- LetR
- Leptin Receptors
- LC/MS/MS
- Liquid Chromatography-Tandem Mass Spectrometry
- NPV
- Negative Predictive Value
- PlGF
- Placental Growth Factor
- PPV
- Positive Predictive Value
- PE
- Preeclampsia
- sFlt-1
- Soluble fms-Like Tyrosine Kinase
- TG
- Triglyceride
- Wk
- Week
